3 terminated, 1 not yet recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Alflutinib: new trials by email Literature Review of Alflutinib trials Research Report on Alflutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases Furmonertinib, Osimertinib - Lung Cancer, Nonsmall Cell | Phase 2 | Not yet recruiting | Taizhou Hospital | 255 | 2024-04-01 | 2024-03-20 |
| Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M Alflutinib - Advanced NSCLC Patients With T790M | Phase 2 | Terminated | Allist Pharmaceuticals, Inc. | 220 | 2018-04-30 | 2025-04-03 |
| AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Alflutinib - Advanced NSCLC | Not applicable | Terminated | Allist Pharmaceuticals, Inc. | 116 | 2017-06-01 | 2025-04-03 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer Alflutinib - NSCLC | Phase 1 | Terminated | Allist Pharmaceuticals, Inc. | 14 | 2016-12-30 | 2025-04-03 |
Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
Allist Pharmaceuticals, Inc. (3) · Taizhou Hospital (1)
China (2)
Shi YK (1)